CD274 and squamous cell carcinoma: Pembrolizumab is an anti-PD1 humanized monoclonal antibody that has recently been granted FDA approval after clinical trials in patients with advanced lung adenocarcinoma or squamous carcinoma that expressed PD-L1 on viable tumor cells, evaluated with a validated assay.